A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating Metastatic CRC Patients

This study is testing a new treatment — a combination of immune checkpoint inhibitor drugs given directly into tumors through a minimally invasive procedure — for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this approach can help patients whose cancer has not responded to previous therapies. **You may be eligible if...** - You are 18 or older - You have colorectal cancer that has spread or cannot be removed surgically - You have already tried standard chemotherapy (fluorouracil, oxaliplatin, or irinotecan) and targeted drugs, and your cancer has progressed - Your tumor has specific genetic features (dMMR or MSI-H) and has also progressed after immune checkpoint therapy (anti-PD-1 or anti-PD-L1) - You have acceptable organ function **You may NOT be eligible if...** - You have not yet tried standard treatments - Your cancer does not have the required genetic features - You have severe liver, kidney, or blood count problems Talk to your doctor to see if this trial is right for you.